Five Prime Therapeutics, Inc. (FPRX) is a Major Pharmaceuticals company listed on NASDAQ. There were no new wire items for FPRX in the last 30 days. The most recent was published Jan 4, 2022.
Latest news
25 items- PRApexigen Announces Appointment of Francis Sarena as Chief Operating OfficerSAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut
- SECSEC Form SC 13G/A filed by Five Prime Therapeutics, Inc. (Amendment)SC 13G/A - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Subject)
- SECSEC Form 15-12B filed by Five Prime Therapeutics, Inc.15-12B - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
- SECSEC Form EFFECT filed by Five Prime Therapeutics, Inc.EFFECT - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
- INSIDERSEC Form 4: Sarena Francis Willard received a gift of 2,385 units of Common Stock, was granted 66,000 units of Common Stock, disposed of $6,530,414 worth of Common Stock back to the company (171,853 units at $38.00) and gifted 20,459 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy withholding obligation4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4: Smith David V was granted 66,000 units of Common Stock and disposed of $5,279,986 worth of Common Stock back to the company (138,947 units at $38.00) , decreasing direct ownership by 100% to 0 units to satisfy tax liability4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4: Collins Helen Louise disposed of $5,150,786 worth of Common Stock back to the company (135,547 units at $38.00) , gifted 8,085 units of Common Stock and was granted 66,000 units of Common Stock, decreasing direct ownership by 100% to 0 units to satisfy tax liability4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4: White David disposed of $1,270,074 worth of Common Stock back to the company (33,423 units at $38.00) , decreasing direct ownership by 100% to 0 units (tax withholding)4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4: RINGO WILLIAM R gifted 10,000 units of Common Stock, decreasing direct ownership by 100% to 0 units4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4: BERGER FRANKLIN M disposed of $190,000 worth of Common Stock back to the company (5,000 units at $38.00) , decreasing direct ownership by 100% to 0 units to satisfy tax liability4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4 filed by Dhingra Kapil4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4 filed by Jensen Peder4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4 filed by Nicholson Garry A4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4 filed by SCHAFER CAROL4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4 filed by Lyons-Williams Lori4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- INSIDERSEC Form 4: Civik Thomas disposed of $2,620,898 worth of Common Stock back to the company (68,971 units at $38.00) , decreasing direct ownership by 100% to 0 units (tax withholding)4 - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Issuer)
- SECSEC Form S-8 POS filed by Five Prime Therapeutics, Inc.S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
- SECSEC Form S-8 POS filed by Five Prime Therapeutics, Inc.S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
- SECSEC Form S-8 POS filed by Five Prime Therapeutics, Inc.S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
- SECSEC Form S-8 POS filed by Five Prime Therapeutics, Inc.S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
- SECSEC Form S-8 POS filed by Five Prime Therapeutics, Inc.S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
- SECSEC Form S-8 POS filed by Five Prime Therapeutics, Inc.S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
- SECSEC Form S-8 POS filed by Five Prime Therapeutics, Inc.S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
- SECSEC Form S-8 POS filed by Five Prime Therapeutics, Inc.S-8 POS - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
- SECSEC Form POS AM filed by Five Prime Therapeutics, Inc.POS AM - FIVE PRIME THERAPEUTICS, INC. (0001175505) (Filer)
FPRX FAQ
6 questionsWhat is the latest news on FPRX?
Quantisnow has not tracked any new filings, ratings or press releases for FPRX in the last 30 days. The most recent wire item was published on January 4, 2022.Where does FPRX stock trade?
Five Prime Therapeutics, Inc. (FPRX) is listed on NASDAQ.What sector and industry is FPRX in?
Five Prime Therapeutics, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Five Prime Therapeutics, Inc. go public?
Five Prime Therapeutics, Inc. (FPRX) completed its IPO in 2013.What companies are similar to FPRX?
Notable peers in the same industry include ADMS (Adamas Pharmaceuticals, Inc.), ADRO (Aduro Biotech, Inc.), ADXS (Advaxis, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.), AIMT (Aimmune Therapeutics, Inc.). Compare FPRX side-by-side with any of them on Quantisnow.How can I track FPRX on Quantisnow?
Quantisnow aggregates Five Prime Therapeutics, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FPRX to receive live email and push alerts on every new disclosure.